Obstructive Sleep Apnea/Hypopnea Syndrome Clinical Trial
Official title:
Comparison of Vascular Risk in Patients Treated for Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS) With Continuous Positive Airway Pressure (CPAP) and Mandibular Advancement Orthosis
a monocentric,non interventional, prospective study to compare cardiovascular risk in patients with Obstructive Sleep Apnea/Hypopnea Syndrome treated with Continuous Positive Airway Pressure (CPAP) and Mandibular Advancement Orthosis.
The first-line treatment of severe Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS) is nocturnal ventilation with Continuous Positive Airway Pressure (CPAP). and The second-line treatment is the mandibular advancement orthosis (MAO)]. CPAP is the most effective treatment to reduce the apnea-hypopnea index (AHI). However, its tolerance is sometimes difficult, causing many discontinuations. The purpose of this review is to evaluate a vascular morbimortality criteria: - Cardiovascular: myocardial infarction, heart failure, rhythm disorder - Neurological: transient or non transient stroke - ophthalmologic: anterior ischemic optic neuropathy, occlusion of the central artery or central retinal vein occlusion ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00228553 -
Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness
|
Phase 3 |